Pathogenesis of myasthenia gravis;Patogénesis de la miastenia gravis

Revista de Investigacion Clinica

Volumn 52, Issue 1, 2000, Pages 80-85

  Téllez Zenteno, José Francisco ^a   Morales Buenrostro, Luis Eduardo ^a   Torre Delgadillo, Aldo ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Autoimmune disease; Etiology; Myasthenia gravis

Indexed keywords

CHOLINERGIC RECEPTOR;

HUMAN; IMMUNOLOGY; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; REVIEW;

HUMANS; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; RECEPTORS, CHOLINERGIC;

EID: 0347900738     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Simpson JA. Myasthenia gravis. A new hypothesis. Scot Med J 1960; 4: 419-36.
2. Nastuk WL, Plescia OJ, Osserman KE. Changes in the serum complement activity in patients with myasthenia gravis. Proc Soc Exp Bio Med 1960; 105: 177-84.
3. Katz B, Miledi R. The release of acetylcholine from nerve endings by graded electric pulses. Proc R Soc Lond [B] 1967; 167: 27-38.
4. Chang CC, Lee C-Y. Electrophysiological study of neuromuscular blocking with cobra neurotoxin. Br J Pharmacol Chemother 1966;28:172-81.
5. Changeux J-O, Kasai N, Lee C-Y. Use of a snake venom toxin to characterize the cholinergic receptor protein. Proc Natl Aced Sci USA 1970; 67: 1241-7.
6. Patrick J, Linstrom J. Autoimmune response to acetylcholine receptor. Science 1973; 180: 871-2.
7. Fambrough DM, Drachman DB, Pestronk A, Kao I. Myasthenia gravis: passive transfer from man to mouse. Science 1975; 190: 397-9.
8. Linsdtrom JM, Engel AG, Seybold ME et al. Pathological mechanism in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J Exp Med 1976; 144: 739-53.
9. Tokya KV, Drachman DB, Pestronk A, Kao I. Myasthenia gravis, passive transfer from man to mouse. Science 1975; 190: 397-9.
10. Lennon VA, Lindstrom JM, Seybold ME. Experimental autoimmune myasthenia, a model of myasthenia gravis in rats and guinea pigs. J Exp Med 1975; 141: 1365-75.
11. Engel AG, Tsujihata M, Linsdtrom JM et al. The motor endplate in myasthenia gravis and in experimental autoimmune myasthenia gravis; a quantitative ultrastructural study. Ann NY Acad Sci 1976; 274: 60-79.
12. Kendel E, Siegelbaum S. Directly Gated Transmission at the Nerve-Muscle Synapse. En: Kandel E, Schwartz J, Jessell T. Principles of Neural Science. Third Edition; Appleton & Langle Norwalk, Connecticut. 1991; 135-52.
13. Kaminski H, Suárez J, Ruff R. Neuromuscular junction physiology in myasthenia gravis. Neurology 1997; 48(Suppl 5): S8-S17.
14. Unwin N. Neurotransmitter action: opening of ligand-gated ion channels. Cell 1993; 72: 31-4.
15. Unwin. Acethylcholine receptor channel imaged in the open state. Nature 1995; 373(72): 31-4.
16. Toyoshima C, Unwin N. Ion channel of acetylcholine receptor: distinct conformations of the a subunits. J Mol Biol 1996; 257: 586-96.
17. Unwin N. Projection structure of the nicotinic acethylcholine receptor; distinct conformations of the a subunit. J Mol Biol 1996; 336: 247-50.
18. Witzeman V, Barg B, Criado M, Stein E, Sakmann B. Developmental regulation of five subunits specific mRNAs encoding acetylcholine receptor subtypes in rat muscle. FEBS Lett 1989; 242: 419-24.
19. Guy HR, Hucho F. The ion channel of nicotinic acetylcholine receptor. Trends Neurosci 1987; 10: 318-22.
20. Dani JA. Site directed mutagenesis and single-channel currents define the ion channel of the nicotinic acetylcholine receptor. Trends Neurosci 1989; 12: 125-30.
21. Tzartos SJ, Cung MT, Demange P et al. The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies. Mol Neurobiol 1991; 5: 1-29.
22. Beroukhim R, Unwin N. Three-dimensional location of the main immunogenic region of the acetylcholine receptor. Neuron 1995; 15: 323-31.
23. Lennon V. Serologic profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome. Neurology 1997; 48(Suppl 5): S23-S27.
24. Vincent A, Newson-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 cases and 2.967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985; 48: 1246-52.
25. Engel AG, Sahashi K, Lambert EH, Howard FM. The ultrastructural localization of the acetylcholine receptor, immunoglobulin G and the third and nine complement components at the motor end-plate and their implications for the pathogenesis of myasthenia gravis. In: Aguayo AJ, Karpati G eds. Current topics in nerve and muscle research. Amsterdam. Excerpta Medico 1979: 111-22.
26. Tokya KV, Drachman DB, Griffin DE et al. Myasthenia gravis, study of humoral immune mechanisms by passive transfer to mice. N Eng J Med 1977; 296: 125-31.
27. Sanders D, Scoppeta C. The treatment of patients with myasthenia gravis. Neurologic Clinics 1994; 12(2): 343-68.
28. Lenon V. Serologic profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome. Neurology 1997; 48(Suppl 5): S23-S27.
29. Drachman DB, Adams RN, Josifek LF, Self SG. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Eng J Med 1982; 307: 769-75.
30. Howard FM Jr, Lennon VA, Finley J, Matsumoto J, Elveback LR. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci 1987; 505: 526-38.
31. Engel AG, Arahata K. The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci 1987; 505: 326-32.
32. Wang ZY, Karachunski P, Hoeard J, Conti-Fine B. Myasthenia in SCID mice grafted with myasthenic patient lymphocytes. Neurology 1999; 52: 484-97.
33. Hohlfeld R. Myasthenia gravis. Cell transfer from man to mouse. Neurology 1999; 52: 443-5.
34. Sanders D, Andrews I, Howard J, Massey J. Seronegative myasthenia gravis. Neurology 1997; 48(Suppl 5): S40-S45.
35. Burges J, Vincent A, Molenar P, Newson-Davios J, Peers C, Wray D. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 1994; 17: 1393-400.
36. Massey J. Acquired Myasthenia Gravis. Neurologic Clinics 1997; 15(3): 577-95.
37. Jaretzki A. Thymectomy for myasthenia gravis. Neurology 1997; 49(Suppl 5): S52-S63.
38. Sommer N, Willcox N, Harcourt GC, Newson-Davis J. Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor reactivity T cells. Ann Neurol 1990; 28: 312-9.
39. Aoki T, Drachman DB, Asher DM, Gibbs CJ Jr, Bahmanyar S, Wolinsky JS. Attempts to implicate viruses in myasthenia gravis. Neurology 1985; 35: 185-92.
40. Schwimmbeck PL, Dyrberg T, Drachman DB, Oldstone MBA. Molecular mimicry and myasthenia gravis; an autoantigenic site of the acetylcholine receptor α-subunit that has biologic activity and reacts immunochemically with herpes simple virus. J Clin Invest 1989; 84: 1174-80.
41. Stefansson K, Dieperink ME, Richman DP, Gomez CM, Marton LS. Sharing of antigenic determinants between the nicotinic acetyl-choline receptor and proteins in Escherichia coli, Proteus vulgaris, and Klebsiella pneumoniae; possible role in the pathogenesis of myasthenia gravis. N Eng J Med 1985; 312: 221-5.
42. Carlsson B, Wallin J, Prskanen R, Matell G, Smith CIE. Different HLA DR-DQ associations in subgroups of idiophatic myasthenia gravis. Immunogenetics 1990; 31: 285-90.